2 months ago
NKTR
AnalystsSamantha SemenkowSamantha Semenkow's Stock Forecasts
AnalystsSamantha Semenkow
Sectors:
Analyst Ranking
Top 20%
#1049 out of 5301 analysts
Average Return
+7.55%
Win Rate
50%38 out of 76
Risk vs Reward
Poor
Good
Samantha Semenkow's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Bioage Labs IncBIOA | +243.31% | $6.05 | $20.77 | 2025-10-22 - 2026-06-18 | Strong Buy |
Bioage Labs IncBIOA | +170.44% | $7.68 | $20.77 | 2025-10-29 - 2026-06-18 | Strong Buy |
Spyre Therapeutics IncSYRE | +167.21% | $33.06 | $88.34 | 2025-12-17 - 2026-06-18 | Strong Buy |
Roivant Sciences LtdROIV | +153.67% | $12.39 | $31.43 | 2025-09-02 - 2026-06-18 | Strong Buy |
Morphic Holding IncMORF | +109.75% | $27.17 | $56.99 | 2023-12-08 - 2024-08-16 | Strong Buy |
Samantha Semenkow Analyst Color
Get additional color on Samantha Semenkow's coverage of popular stocks
3 months ago
NKTR
3 months ago
BIOA
4 months ago
CPRX
4 months ago
ROIV
2 years ago
CABA
2 years ago
EDIT
2 years ago
LRMR
Samantha Semenkow's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Faeth Therapeutics IncFTH | 3 | Strong Buy | $55.00 | +208.64% | Initiates Coverage On | a month ago |
Sab Biotherapeutics IncSABS | 1 | Strong Buy | $11.00 | +175.00% | Initiates Coverage On | a month ago |
Roivant Sciences LtdROIV | 5 | Strong Buy | $42.00 | +33.63% | Maintains | a month ago |
Catalyst Pharmaceuticals IncCPRX | 5 | Hold | $31.50 | +0.38% | Downgrades | a month ago |
Spyre Therapeutics IncSYRE | 2 | Strong Buy | $97.00 | +9.80% | Maintains | 2 months ago |
Wave Life Sciences LtdWVE | 3 | Strong Buy | $24.00 | +289.61% | Maintains | 2 months ago |
Nektar TherapeuticsNKTR | 3 | Strong Buy | $151.00 | +147.62% | Maintains | 2 months ago |
Biohaven LtdBHVN | 3 | Strong Buy | $17.00 | +25.28% | Maintains | 3 months ago |
Beam Therapeutics IncBEAM | 4 | Strong Buy | $68.00 | +99.18% | Maintains | 3 months ago |
Rhythm Pharmaceuticals IncRYTM | 3 | Strong Buy | $142.00 | +46.71% | Maintains | 3 months ago |
Bioage Labs IncBIOA | 6 | Strong Buy | $52.00 | +150.36% | Maintains | 3 months ago |
Agios Pharmaceuticals IncAGIO | 2 | Strong Buy | $46.00 | +34.66% | Maintains | 4 months ago |
Larimar Therapeutics IncLRMR | 7 | Strong Buy | $14.00 | +284.62% | Maintains | 4 months ago |
Cullinan Therapeutics IncCGEM | 1 | Strong Buy | $33.00 | +119.56% | Initiates Coverage On | 4 months ago |
Argenx SeARGX | 8 | Strong Buy | $1,091.00 | +24.30% | Maintains | 5 months ago |
Amicus Therapeutics IncFOLD | 2 | Hold | $14.50 | +0.07% | Downgrades | 6 months ago |
Structure Therapeutics IncGPCR | 2 | Strong Buy | $100.00 | +124.67% | Maintains | 6 months ago |
Prime Medicine IncPRME | 5 | Hold | $4.25 | +31.58% | Maintains | 7 months ago |
Moonlake ImmunotherapeuticsMLTX | 3 | Strong Sell | $5.00 | -73.97% | Downgrades | 8 months ago |
Cabaletta Bio IncCABA | 4 | Strong Buy | $10.00 | +252.11% | Maintains | 10 months ago |
Allogene Therapeutics IncALLO | 3 | Strong Buy | $4.00 | N/A | Maintains | a year ago |
Acelyrin IncSLRN | 2 | Hold | $3.00 | N/A | Maintains | a year ago |
Voyager Therapeutics IncVYGR | 1 | Strong Buy | $12.00 | N/A | Initiates Coverage On | 2 years ago |
Sana Biotechnology IncSANA | 2 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
Editas Medicine IncEDIT | 4 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
2seventy Bio IncTSVT | 2 | Strong Buy | $12.00 | N/A | Maintains | 2 years ago |
Morphic Holding IncMORF | 1 | Strong Buy | $46.00 | N/A | Initiates Coverage On | 3 years ago |
Immunovant IncIMVT | 3 | Strong Buy | $50.00 | N/A | Maintains | 3 years ago |
9 Meters Biopharma IncNMTRQ | 3 | Hold | $0.75 | N/A | Maintains | 3 years ago |
Ngm Biopharmaceuticals IncNGM | 1 | Strong Buy | $6.00 | N/A | Initiates Coverage On | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.